Myriad Genetics Inc (MYGN)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $542.92M
Last updated: Nov 17, 2026 at 11:06 AM ET
Myriad Genetics Inc (MYGN) Competitors
The companies most similar to Myriad Genetics are Fulgent Genetics (FLGT), Castle Biosciences (CSTL) and NeoGenomics (NEO). By market cap, Myriad Genetics ranks 10th of the 13 companies on this page; Natera (NTRA) is the largest at $46.27B. The median P/E of the 3 companies with a P/E is 48.2x.
Peer Comparison
MYGN's ROIC of -29.5% is below the peer median of -5.7%, and its revenue growth of -1.5% is below the median of 13.3%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Myriad Genetics (MYGN) | $542.92M | N/A | 0.7x | -16.1% | -29.5% | -1.5% | 0.00% |
| Fulgent Genetics Inc (FLGT) | $688.98M | N/A | 2.0x | -27.5% | -12.1% | 7.5% | 0.00% |
| Castle Biosciences Inc (CSTL) | $1.04B | N/A | 2.7x | -6.1% | -5.4% | 23.9% | 0.00% |
| NeoGenomics Inc (NEO) | $2.07B | 228.9x | 2.6x | -4.1% | -2.5% | 11.4% | 0.00% |
| Personalis Inc (PSNL) | $1.70B | N/A | 20.9x | -147.7% | N/A | 76.6% | 0.00% |
| Veracyte Inc (VCYT) | $1.96B | 13.3x | 3.3x | 21.8% | 8.2% | 15.1% | 0.00% |
| Opko Health Inc (OPK) | $1.25B | N/A | 2.4x | -22.6% | -6.2% | 15.9% | 0.00% |
| GRAIL, LLC (GRAL) | $5.21B | N/A | 29.6x | -243.8% | N/A | 3.7% | 0.00% |
| MDxHealth SA (MDXH) | $13.75M | N/A | N/A | -38.3% | -40.5% | -17.2% | 0.00% |
| Natera Inc (NTRA) | $46.27B | N/A | 14.3x | -5.7% | -8.5% | 34.1% | 0.00% |
| Insight Molecular Diagnostics Inc. (IMDX) | $70.03M | N/A | 40.9x | 0.0% | 197.8% | -53.9% | 0.00% |
| CareDx Inc (CDNA) | $4.09B | 48.2x | 6.4x | 25.9% | N/A | 39.3% | 0.00% |
| Precipio Inc (PRPO) | $39.68M | N/A | 1.3x | -4.1% | -5.7% | 8.3% | 0.00% |
| Peer median | $1.48B | 48.2x | 3.3x | -5.9% | -5.7% | 13.3% | 0.00% |
Similar Companies
These are the 12 companies most similar to Myriad Genetics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Diagnostics & Research.
| Company | About | Peers |
|---|---|---|
| Fulgent Genetics Inc (FLGT) | Fulgent Genetics, Inc., provides COVID-19 testing and genetic testing services to physicians with clinically actionable diagnostic information. | FLGT competitors |
| Castle Biosciences Inc (CSTL) | Castle Biosciences Inc. is a pioneering diagnostics firm that enhances patient care through advanced gene-expression profiling tests... | CSTL competitors |
| NeoGenomics Inc (NEO) | NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. | NEO competitors |
| Personalis Inc (PSNL) | Personalis, Inc. is a global cancer genomics company. The company is headquartered in Menlo Park, California. | PSNL competitors |
| Veracyte Inc (VCYT) | Veracyte, Inc. is a genomic diagnostics company in the United States and internationally. The company is headquartered in South San Francisco, California. | VCYT competitors |
| Opko Health Inc (OPK) | OPKO Health, Inc., a healthcare company, is engaged in the pharmaceutical and diagnostic businesses in the United States, Ireland, Chile, Spain, Israel, Mexico... | OPK competitors |
| GRAIL, LLC (GRAL) | GRAIL, LLC is a leading biotechnology firm specializing in advanced cancer diagnostics... | GRAL competitors |
| MDxHealth SA (MDXH) | MDxHealth SA is a prominent biotechnology company focused on precision diagnostics that enhance cancer management, particularly in prostate and bladder cancers. | MDXH competitors |
| Natera Inc (NTRA) | Natera, Inc., a diagnostic company, develops and markets molecular testing services globally. The company is headquartered in San Carlos, California. | NTRA competitors |
| Insight Molecular Diagnostics Inc. (IMDX) | OncoCyte Corporation is a precision diagnostics company in the United States and internationally. The company is headquartered in Irvine, California. | IMDX competitors |
| CareDx Inc (CDNA) | CareDx, Inc. discovers, develops and markets diagnostic solutions for transplant patients and caregivers globally. | CDNA competitors |
| Precipio Inc (PRPO) | Precipio, Inc., a cancer diagnostic and reagent technology company, provides diagnostic products and services in the United States oncology market. | PRPO competitors |
Frequently Asked Questions About MYGN
Who are Myriad Genetics' main competitors?
The companies most similar to Myriad Genetics include Fulgent Genetics (FLGT), Castle Biosciences (CSTL), NeoGenomics (NEO), Personalis (PSNL) and Veracyte (VCYT), listed from the closest match.
Who is Myriad Genetics' biggest competitor?
Natera (NTRA) is the largest of the similar companies at $46.27B; Fulgent Genetics (FLGT) is the closest match by business profile, size, sector and industry.
How does MYGN stock compare with its competitors?
MYGN's P/S is 0.7x against a peer median of 3.3x; its net margin is -16.1% against a peer median of -5.9%.
Which of Myriad Genetics' competitors pays a higher dividend?
Myriad Genetics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Myriad Genetics bigger than its competitors?
No. Myriad Genetics is 10th by market cap among the 13 companies on this page; the largest is Natera (NTRA) at $46.27B.
MYGN pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts